Pro Share Advisors LLC Sage Therapeutics, Inc. Transaction History

Pro Share Advisors LLC

  • $39.7 Billion
  • Q3 2024

A detailed history of Pro Share Advisors LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 13,931 shares of SAGE stock, worth $76,202. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,931
Previous 10,796 29.04%
Holding current value
$76,202
Previous $117,000 14.53%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$7.02 - $13.08 $22,007 - $41,005
3,135 Added 29.04%
13,931 $100,000
Q2 2024

Aug 13, 2024
SELL
$10.58 - $17.9 $30,861 - $52,214
-2,917 Reduced 21.27%
10,796 $117,000
Q1 2024

May 08, 2024
BUY
$18.62 - $26.95 $21,040 - $30,453
1,130 Added 8.98%
13,713 $256,000
Q4 2023

Feb 14, 2024
BUY
$17.1 - $22.26 $30,797 - $40,090
1,801 Added 16.7%
12,583 $272,000
Q3 2023

Nov 13, 2023
BUY
$16.75 - $48.98 $653 - $1,910
39 Added 0.36%
10,782 $221,000
Q2 2023

Aug 10, 2023
BUY
$40.65 - $59.54 $19,186 - $28,102
472 Added 4.6%
10,743 $505,000
Q1 2023

May 11, 2023
SELL
$37.27 - $46.57 $50,426 - $63,009
-1,353 Reduced 11.64%
10,271 $430,000
Q4 2022

Feb 02, 2023
BUY
$32.2 - $43.61 $28,400 - $38,464
882 Added 8.21%
11,624 $443,000
Q3 2022

Nov 04, 2022
BUY
$32.28 - $43.27 $9,425 - $12,634
292 Added 2.79%
10,742 $420,000
Q2 2022

Aug 01, 2022
BUY
$27.52 - $37.99 $119,409 - $164,838
4,339 Added 71.0%
10,450 $338,000
Q1 2022

May 10, 2022
SELL
$30.71 - $45.71 $67,070 - $99,830
-2,184 Reduced 26.33%
6,111 $202,000
Q4 2021

Feb 08, 2022
SELL
$37.06 - $47.11 $158,246 - $201,159
-4,270 Reduced 33.98%
8,295 $353,000
Q3 2021

Nov 12, 2021
BUY
$40.26 - $57.37 $82,855 - $118,067
2,058 Added 19.59%
12,565 $557,000
Q2 2021

Aug 13, 2021
BUY
$54.88 - $79.29 $133,303 - $192,595
2,429 Added 30.07%
10,507 $597,000
Q1 2021

May 14, 2021
BUY
$70.65 - $96.76 $3,320 - $4,547
47 Added 0.59%
8,078 $605,000
Q4 2020

Feb 09, 2021
SELL
$58.41 - $89.06 $19,158 - $29,211
-328 Reduced 3.92%
8,031 $695,000
Q3 2020

Nov 13, 2020
SELL
$41.13 - $62.45 $31,875 - $48,398
-775 Reduced 8.48%
8,359 $511,000
Q2 2020

Aug 03, 2020
BUY
$25.95 - $43.15 $27,273 - $45,350
1,051 Added 13.0%
9,134 $380,000
Q1 2020

May 15, 2020
SELL
$26.15 - $77.24 $114,040 - $336,843
-4,361 Reduced 35.05%
8,083 $232,000
Q4 2019

Feb 12, 2020
SELL
$60.18 - $154.77 $165,735 - $426,236
-2,754 Reduced 18.12%
12,444 $898,000
Q3 2019

Nov 12, 2019
SELL
$140.29 - $189.96 $136,361 - $184,641
-972 Reduced 6.01%
15,198 $2.13 Million
Q2 2019

Aug 13, 2019
SELL
$157.85 - $183.09 $497,385 - $576,916
-3,151 Reduced 16.31%
16,170 $2.96 Million
Q1 2019

May 15, 2019
BUY
$89.33 - $163.65 $183,037 - $335,318
2,049 Added 11.86%
19,321 $3.07 Million
Q4 2018

Feb 14, 2019
SELL
$81.94 - $139.71 $279,169 - $475,991
-3,407 Reduced 16.48%
17,272 $1.65 Million
Q3 2018

Nov 14, 2018
BUY
$138.11 - $169.04 $156,202 - $191,184
1,131 Added 5.79%
20,679 $2.92 Million
Q2 2018

Aug 13, 2018
SELL
$140.36 - $175.76 $982,660 - $1.23 Million
-7,001 Reduced 26.37%
19,548 $3.06 Million
Q1 2018

May 14, 2018
SELL
$152.15 - $192.33 $226,247 - $285,994
-1,487 Reduced 5.3%
26,549 $4.28 Million
Q4 2017

Feb 14, 2018
BUY
$60.72 - $167.34 $277,551 - $764,911
4,571 Added 19.48%
28,036 $4.62 Million
Q3 2017

Nov 13, 2017
BUY
$61.4 - $88.52 $76,320 - $110,030
1,243 Added 5.59%
23,465 $1.46 Million
Q2 2017

Aug 11, 2017
BUY
N/A
22,222
22,222 $1.77 Million

Others Institutions Holding SAGE

# of Institutions
198
Shares Held
46.5M
Call Options Held
402K
Put Options Held
209K
View Full List

About Sage Therapeutics, Inc.

SAGE Quotes by TradingView
  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $325M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email